A Stanford team reports that blocking an age linked protein rebuilt cartilage in old mice and in cartilage from human knees. The data reframes osteoarthritis as a treatable biology problem, but a human OA trial does not yet exist.
Osteoarthritis is the disease medicine has run out of ideas on. The knee wears down, the cartilage stops cushioning the joint, and the path forward narrows to pain pills, steroid shots, hyaluronic acid, and finally a surgeon replacing the whole hinge. There is no drug that slows the disease, let alone reverses it. Roughly one in five US adults lives with OA, and direct US healthcare spending runs about $65 billion a year, according to the Stanford Medicine-led team summarizing their new Science paper.
A study published today in Science points to a different path. Stanford researchers report that blocking a single protein, 15-PGDH, lets cartilage cells in old mice rebuild the smooth, load-bearing surface that OA erodes. The same treatment, applied to cartilage scraped from human knees during replacement surgery, coaxed those human cells to make new, functional cartilage too. The data is preclinical. It is also, by the standards of a field littered with failed mouse-to-human attempts, unusually clean.
The target is one Helen Blau's lab has been chasing for years. In 2023, her group coined the term "gerozyme" for proteins that climb with age and drag tissues down with them. 15-PGDH degrades prostaglandin E2, a lipid signal that helps many tissues regenerate. When 15-PGDH rises, PGE2 falls. When you block 15-PGDH, PGE2 rises, and the cells around it behave younger. The team has used that lever in muscle, bone, nerve, colon, and liver. Cartilage, the smooth white cap that lets a knee glide, was the next test.
In the new work, 15-PGDH levels roughly doubled in the cartilage of old mice compared with young ones, the Stanford team reports. Injecting a small-molecule 15-PGDH inhibitor, both into the joint and into the abdomen, thickened the aged cartilage and made it hyaline, the right kind, not the scar-like fibrocartilage that foils many repair attempts. In a mouse model of ACL injury, four weeks of twice-weekly treatment after the ligament tear prevented the osteoarthritis that untreated injured mice developed within the same window. The treated mice walked more evenly and put more weight on the injured leg. The untreated injured mice did not.
The human evidence is thinner and needs to be read carefully. The researchers took cartilage discarded from patients getting knee replacements, exposed it to the inhibitor in the lab, and watched the chondrocytes begin laying down fresh matrix. That is ex vivo work: cells outside the body, in a dish, not a treatment in a living patient. It says the same molecular switch is present and operative in human tissue. It does not say the drug works, is safe, or will help a person with OA.
The most concrete signal that this is not pure mouse science sits outside the joint. An oral 15-PGDH inhibitor is already in human clinical trials for sarcopenia, the age-related loss of muscle strength. The same drug class is being tested in people, just for a different disease. That is the kind of translation datapoint an OA program can be built on, because the safety profile and human dosing are being established in a parallel indication. It is not, and the authors do not claim it is, an OA trial.
The team behind the paper is well placed to push it. Senior authors are Helen Blau, who directs the Baxter Laboratory for Stem Cell Biology at Stanford, and Nidhi Bhutani, an associate professor of orthopedic surgery. The lead authors are Mamta Singla, now an instructor in Bhutani's group, and Yu Xin (Will) Wang, who has moved to the Sanford Burnham Institute. Their long game is explicit: either an injection into the knee or an oral drug that lets a chondrocyte keep doing its job instead of slowly failing at it.
The honest version of what to take from this is small enough to hold in one hand. Cartilage biology has a long record of mouse studies that looked decisive and never made it to a human therapy. No one with a creaking knee should read this and stop planning around the realistic options. The honest version of what to take from this is also large enough to be worth paying attention to. A single, druggable molecular target, expressed in human cartilage, with the same target already in human trials for an adjacent disease, is a real start. The next things to watch are whether the sarcopenia trial reads out safely, whether the Blau and Bhutani groups can line up an intra-articular formulation aimed at early OA, and whether a first-in-human OA study gets registered. If those things happen, joint replacement stops being the only ending point in the story.